Roundview Capital LLC raised its position in Amgen, Inc. (NASDAQ:AMGN) by 8.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,849 shares of the medical research company’s stock after purchasing an additional 375 shares during the period. Roundview Capital LLC’s holdings in Amgen were worth $1,005,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kwmg LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at about $108,000. Mainstay Capital Management LLC ADV acquired a new stake in shares of Amgen in the 2nd quarter valued at about $111,000. Polaris Greystone Financial Group LLC acquired a new stake in shares of Amgen in the 3rd quarter valued at about $166,000. Dixon Hubard Feinour & Brown Inc. VA acquired a new stake in shares of Amgen in the 2nd quarter valued at about $200,000. Finally, Family Firm Inc. acquired a new stake in shares of Amgen in the 2nd quarter valued at about $202,000. 77.91% of the stock is currently owned by hedge funds and other institutional investors.

Amgen stock opened at $194.91 on Tuesday. Amgen, Inc. has a 52 week low of $163.31 and a 52 week high of $210.19. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. The stock has a market cap of $123.74 billion, a P/E ratio of 13.99, a price-to-earnings-growth ratio of 2.02 and a beta of 1.37.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The business had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. During the same quarter last year, the company posted $3.27 earnings per share. Amgen’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts predict that Amgen, Inc. will post 14.24 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date is Thursday, November 15th. Amgen’s payout ratio is currently 41.97%.

A number of analysts recently issued reports on AMGN shares. Cann reaffirmed a “buy” rating and issued a $224.00 target price on shares of Amgen in a research report on Monday, July 30th. Citigroup lifted their target price on Amgen from $200.00 to $204.00 and gave the company a “neutral” rating in a research report on Thursday, November 1st. Royal Bank of Canada lowered their target price on Amgen to $182.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 31st. Oppenheimer reaffirmed a “buy” rating and issued a $224.00 target price on shares of Amgen in a research report on Tuesday, August 28th. Finally, Mizuho reaffirmed a “buy” rating and issued a $200.00 target price on shares of Amgen in a research report on Friday, July 27th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $204.55.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/11/20/roundview-capital-llc-purchases-375-shares-of-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

See Also: Understanding debt-to-equity ratio in fundamental analysis

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.